Skin Cancer Playlist

Explore practical strategies for treating melanoma in both the adjuvant and metastatic settings through a series of expert opinion videos that address interpretation of clinical trial data, as well as treatment selection and sequencing.

1. How do you treat patients who have progressed within 6 months of adjuvant anti-PD1 therapy? 
    Answered by Dr. John Walker

2. What is the optimal treatment sequencing for BRAF-mutated disease in the metastatic setting?
    Answered by Dr. John Walker

3. What is the clinical relevance of TFS and the TFI?
    Answered by Dr. John Walker

4. How does the length of follow-up in clinical trial data impact your treatment selection?
    Answered by Dr. John Walker

5. How do you select which patients to treat in the adjuvant setting?
    Answered by Dr. Robyn Macfarlane

6. What is the clinical relevance of RFS in the absence of OS data?
    Answered by Dr. Robyn Macfarlane

7. How will the introduction of anti-LAG-3 therapy impact treatment selection after anti-PD1 therapy?
    Answered by Dr. Robyn Macfarlane

8. What is the MOA of LAG3?
    Answered by Dr. Robyn Macfarlane

BRAF: v-raf murine sarcoma viral oncogene homolog B1 - LAG-3: lymphocyte-activation gene 3 - OS: overall survival - MOA: mechanism of action - PD1: programmed cell death protein 1 - RFS: recurrence-free survival - TFI: treatment-free interval - TFS: treatment-free survival